Total Payments
$173,885
2024 Payments
$81,684
Companies
52
Transactions
2,916
Medicare Patients
4,232
Medicare Billing
$1.9M
Payment Breakdown by Category
Research$75,059 (43.2%)
Food & Beverage$48,137 (27.7%)
Consulting$39,154 (22.5%)
Travel$7,514 (4.3%)
Other$3,540 (2.0%)
Education$481.11 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $75,059 | 4 | 43.2% |
| Food and Beverage | $48,137 | 2,825 | 27.7% |
| Consulting Fee | $39,154 | 18 | 22.5% |
| Travel and Lodging | $7,514 | 34 | 4.3% |
| Honoraria | $3,000 | 2 | 1.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $540.00 | 14 | 0.3% |
| Education | $481.11 | 19 | 0.3% |
Payments by Type
General
$98,826
2,912 transactions
Research
$75,059
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $41,773 | 3 | $0 (2024) |
| SANOFI US SERVICES INC. | $33,286 | 1 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $27,798 | 197 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $11,046 | 160 | $0 (2024) |
| UCB, Inc. | $9,916 | 219 | $0 (2024) |
| Amgen Inc. | $7,924 | 467 | $0 (2024) |
| Horizon Therapeutics plc | $6,071 | 148 | $0 (2023) |
| Regeneron Pharmaceuticals, Inc. | $5,416 | 10 | $0 (2019) |
| ABBVIE INC. | $4,931 | 216 | $0 (2024) |
| Janssen Biotech, Inc. | $3,049 | 171 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $81,684 | 272 | Eli Lilly and Company ($41,773) |
| 2023 | $11,435 | 322 | E.R. Squibb & Sons, L.L.C. ($2,839) |
| 2022 | $14,471 | 322 | Novartis Pharmaceuticals Corporation ($5,403) |
| 2021 | $5,548 | 335 | Amgen Inc. ($853.03) |
| 2020 | $6,482 | 321 | Horizon Therapeutics plc ($1,895) |
| 2019 | $30,874 | 453 | Novartis Pharmaceuticals Corporation ($11,007) |
| 2018 | $13,820 | 525 | Novartis Pharmaceuticals Corporation ($5,343) |
| 2017 | $9,572 | 366 | Novartis Pharmaceuticals Corporation ($4,098) |
All Payment Transactions
2,916 individual payment records from CMS Open Payments — Page 1 of 117
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Eli Lilly and Company | TALTZ (Drug) | — | Cash or cash equivalent | $38,983.00 | Research |
| Study: EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) • Category: Immunology | ||||||
| 12/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $810.00 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $24.60 | General |
| Category: Inflammation | ||||||
| 12/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $26.73 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/15/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: Immunology | ||||||
| 12/15/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Immunology | ||||||
| 12/14/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $138.74 | General |
| Category: Dermatology | ||||||
| 12/12/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $21.62 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/11/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $22.74 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $30.10 | General |
| Category: Dermatology | ||||||
| 12/09/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: Bone Health | ||||||
| 12/06/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $19.60 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $24.48 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/04/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $15.68 | General |
| Category: Immunology | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $20.53 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/03/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: Immunology | ||||||
| 12/02/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $27.90 | General |
| Category: Inflammation | ||||||
| 12/02/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $22.78 | General |
| Category: IMMUNOLOGY | ||||||
| 11/25/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $7.94 | General |
| Category: Bone Health | ||||||
| 11/22/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $11.45 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/19/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $26.17 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $25.22 | General |
| Category: Inflammation | ||||||
| 11/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $26.19 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $10.97 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | Eli Lilly and Company | $41,772 | 2 |
| Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | SANOFI US SERVICES INC. | $33,286 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY | Eli Lilly and Company | $1.62 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 2,182 | 174,730 | $6.0M | $1.7M |
| 2022 | 5 | 523 | 1,900 | $189,991 | $76,931 |
| 2021 | 5 | 610 | 689 | $152,596 | $61,830 |
| 2020 | 9 | 917 | 1,033 | $143,171 | $54,130 |
Total Patients
4,232
Total Services
178,352
Medicare Billing
$1.9M
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 45 | 101,800 | $1.5M | $397,245 | 26.6% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 21 | 10,550 | $1.3M | $345,176 | 27.4% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 44 | 30,360 | $1.2M | $317,106 | 26.6% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 21 | 20,430 | $599,040 | $164,874 | 27.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 86 | 7,860 | $465,480 | $146,093 | 31.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 848 | 1,375 | $371,250 | $127,523 | 34.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 522 | 575 | $209,300 | $68,627 | 32.8% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 147 | 827 | $156,114 | $45,276 | 29.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 97 | 446 | $153,870 | $43,209 | 28.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 153 | 153 | $63,495 | $18,767 | 29.6% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 12 | 79 | $8,690 | $1,686 | 19.4% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 23 | 27 | $4,900 | $1,290 | 26.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 18 | 22 | $5,940 | $1,062 | 17.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 15 | $2,760 | $865.84 | 31.4% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 64 | 74 | $2,960 | $614.62 | 20.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 50 | 57 | $3,648 | $545.24 | 14.9% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 16 | 80 | $1,660 | $508.31 | 30.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 328 | 441 | $97,629 | $36,490 | 37.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 14 | 1,260 | $41,580 | $21,644 | 52.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 140 | 140 | $43,120 | $15,222 | 35.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 22 | 26 | $6,474 | $3,211 | 49.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 19 | 33 | $1,188 | $364.65 | 30.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 353 | 397 | $84,267 | $35,557 | 42.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 198 | 198 | $60,984 | $23,367 | 38.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 22 | 22 | $5,478 | $2,315 | 42.3% |
About Dr. Jitendra Vasandani, MD
Dr. Jitendra Vasandani, MD is a Rheumatology healthcare provider based in Lubbock, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1194707406.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jitendra Vasandani, MD has received a total of $173,885 in payments from pharmaceutical and medical device companies, with $81,684 received in 2024. These payments were reported across 2,916 transactions from 52 companies. The most common payment nature is "" ($75,059).
As a Medicare-enrolled provider, Vasandani has provided services to 4,232 Medicare beneficiaries, totaling 178,352 services with total Medicare billing of $1.9M. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Lubbock, TX
- Active Since 11/14/2005
- Last Updated 03/01/2023
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1194707406
Products in Payments
- TALTZ (Drug) $40,027
- COSENTYX (Biological) $26,395
- Cimzia (Drug) $7,916
- ORENCIA (Biological) $7,138
- KRYSTEXXA (Biological) $6,188
- KEVZARA (Biological) $5,862
- Enbrel (Biological) $4,216
- BENLYSTA (Biological) $2,334
- XELJANZ (Drug) $2,023
- SAPHNELO (Biological) $1,904
- RINVOQ (Biological) $1,885
- TREMFYA (Drug) $1,430
- KEVZARA (Drug) $1,206
- EVENITY (Biological) $1,198
- ACTHAR (Biological) $1,183
- Rituxan (Biological) $1,177
- Humira (Biological) $1,096
- SIMPONI ARIA (Biological) $986.86
- SKYRIZI (Biological) $848.52
- COSENTYX (Drug) $827.55
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Lubbock
Dr. James Calmes, Md, Mba, MD, MBA
Rheumatology — Payments: $7,522
Rheumatology $7,522
Dr. Jose Del Giudice, Md, MD
Rheumatology — Payments: $4,704
Rheumatology $4,704
Dr. Naga Bushan, Md, MD
Rheumatology — Payments: $4,478
Rheumatology $4,478
Christina Pauda
Rheumatology — Payments: $3,600
Rheumatology $3,600
John Pixley, M.d, M.D
Rheumatology — Payments: $129.71
Rheumatology $129.71